I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Home Ophthalmology Retina Society 2026
Roche and Genentech at

Retina Society 2026

September 23 - September 26
Los Angeles, USA
retinasociety.org
We will be contributing to topics related to
Ophthalmology
-
Agenda
Medical Materials
03:44 PM
Duration 4mins Los Angeles, USA
Faricimab▼ for Polypoidal Choroidal Vasculopathy: 2-Year Results From the Phase 3b/4 SALWEEN Trial
Colin Tan, Timothy Y. Y. Lai, Gemmy Cheung, Shih-Jen Chen, Shigeru Honda, Adrian Hock Chuan Koh, Won Ki Lee, Xiaorong Li, Paisan Ruamviboonsuk, Min Sagong, Xiaodong Sun, Yasuo Yanagi, Ruobing Bai, Xiaoying Yang, Philippe Margaron
Ophthalmology | Polypoidal Choroidal Vasculopathy
Share page
06:48 PM
Duration 4mins Los Angeles, USA
Long-Term Real-World Effectiveness of Faricimab▼ in Patients With Neovascular Age-Related Macular Degeneration: 2-Year Results From the FARETINA-nAMD and FARWIDE nAMD Studies
Ali F, Borkar D, Bonine N, Ko S, Ahmed A, Amador M, Patel S, Zwick E, Toth J, Leng T, Singh R, Talks J, Varma D, Gale R, Patel P, De Salvo G, De Silva S, Chi G, Darnell A, Dodds M, Dayal P
Ophthalmology | Neovascular Age Related Macular Degeneration
Share page
07:00 PM
Duration 4mins Los Angeles, USA
Up to 7-Year Retinal Fluid Outcomes in Patients With Neovascular Age-Related Macular Degeneration treated with the Port Delivery Platform With Ranibizumab: Results from the Portal Extension Trial
Jeremy Wolfe, Gian-Andrea Thanei, Jeremy Wolfe, María Dolores Berger Lassalle, Mel Rabena, Natasha Singh, Shamika Gune, Steven Blotner
Ophthalmology | Neovascular Age Related Macular Degeneration
Share page
07:04 PM
Duration 4mins Los Angeles, USA
Port Delivery Platform With Ranibizumab Treatment in Eyes With Neovascular Age-Related Macular Degeneration and High Injection Burden
Yasha Modi, M Klufas, Jeffrey Moore, Robert Wirthlin, S Blotner, B Chin, A Gordon, S Gune
Ophthalmology | Neovascular Age Related Macular Degeneration
Share page
09:30 PM
Duration 4mins Los Angeles, USA
Visual Acuity Outcomes at Week 16 of the Phase 3 MEERKAT and SANDCAT Trials of Vamikibart in Patients With Uveitic Macular Edema
Glenn J. Jaffe, Rahul N. Khurana, Lyndell Lim, Deanna Galloway, Emma Harrell, Ivo Stilov, Zdenka Haskova, David Silverman, Laura Steeples, Eric Suhler
Ophthalmology | Uveitic Macular Edema
Share page
09:34 PM
Duration 4mins Los Angeles, USA
Vamikibart in Patients With Uveitic Macular Edema in the Phase 3 MEERKAT and SANDCAT Trials: Durability of Response 8 Weeks After the Last Per-Protocol Injection
Quan Dong Nguyen, Do B, Suhler E, Acharya N, Pavesio C, Sonoda KH, Galloway D, Haskova Z, Harrell E, Mesquida M, Silverman D, Stoilov I, Vicente A, Steeples L, Khurana R
Ophthalmology | Uveitic Macular Edema
Share page
11:00 PM
Duration 4mins Los Angeles, USA
Pagoda Trial Results Through Year 4: Port Delivery Platform With Ranibizumab for the Treatment of Diabetic Macular Edema
Kevin J Blinder, Lindsell L, Pieramici D, Gune S, Jones M, Liu W, Tarakegn S, Tian K
Ophthalmology | Diabetic Macular Edema
Share page
03:21 PM
Duration 3mins Los Angeles, USA
Reduction in Subretinal Hyperreflective Material Volume With Faricimab▼ vs Aflibercept 2 mg in Treatment-Naïve nAMD: A TENAYA/LUCERNE Analysis
Michael Ammar, Charles Eifrig, Jesse Jung, Nirojini Sivachandran, Isabel Bachmeier, Lei Han, Andreas Maunz, Shriji Patel, Siqing Yu, Philippe Margaron, SrinVas Sadda
Ophthalmology | Neovascular Age Related Macular Degeneration
Share page
03:24 PM
Duration 3mins Los Angeles, USA
Better Visual Outcomes With Faricimab▼ vs Aflibercept 2 mg in Patients With Treatment-Naïve nAMD Who Had Small Lesions in TENAYA/LUCERNE
Manjot Gill, Eric Nudleman, Nicholas Dagincourt, Florie Mar, Shriji Patel, Philippe Margaron
Ophthalmology | Neovascular Age Related Macular Degeneration
Share page
05:37 PM
Duration 3mins Los Angeles, USA
Assessment of Intraretinal Cyst Turbidity on Optical Coherence Tomography: Clinical Implications in Eyes With DME From the YOSEMITE/RHINE Trials
Avni Patel Finn, Vas Sadda, Andreas Pollreisz, Jenny Lim, Isabel Bachmeier, Yaniv Cohen, Ali Boushehri, Manuel Amador, Alexandra Warter, Nicholas Dagincourt, Kara Gibson
Ophthalmology | Diabetic Macular Edema
Share page
05:40 PM
Duration 3mins Los Angeles, USA
Quantitative Analysis of Capillary Vessel Density, Microaneurysms, and Intraretinal Microvascular Abnormalities Following Faricimab▼ in Treatment-Naïve DME: An ALTIMETER OCT-A Post Hoc Analysis
Patricio Schlottmann, Le Boité H, Gallardo M, Eap M, Gibson K, Yang M, Patel S, Titz B, Benech A, Vazquez-Lombardi C, Couturier A
Ophthalmology | Diabetic Macular Edema
Share page
05:43 PM
Duration 3mins Los Angeles, USA
Impact of Baseline Subretinal Fluid on Treatment Outcomes in DME: Analysis of the Phase 3 YOSEMITE and RHINE Trials
Clement Chan, Medrano JR, Alabi R, Han L, Warter A, Amador M, Gibson K
Ophthalmology | Diabetic Macular Edema
Share page
05:49 PM
Duration 4mins Los Angeles, USA
Outcomes for Continuous Ranibizumab Delivery via the Port Delivery Platform in Diabetic Eyes Undergoing Vitrectomy for Vitreous Hemorrhage
Dennis Marcus, Blotner S, Bobbala A, Gune S, Lassalle D, Latkany P, Maass K
Ophthalmology | Diabetic Retinopathy
Share page
03:06 PM
Duration 4mins Los Angeles, USA
Long-Term Real-World Effectiveness of Faricimab▼ in Patients With Diabetic Macular Edema: 2-Year Results From FARETINA-DME and FARWIDE-DME Studies
Rao P, Patel S, Singh R, Bonine N, Ko S, Ahmed A, Amador M, Zwick E, Toth J, Ali F, Leng T, Borkar D, Peto T, Bailey C, Pearce I, Reynolds R, Sivaprasad S, Kiire C, Downey L, Chi G, Darnell A, Dodds M, Dayal P
Ophthalmology | Diabetic Macular Edema
Share page
03:24 PM
Duration 4mins Los Angeles, USA
Baseline Biomarker Levels in Underrepresented Patients With DME: An Exploratory Analysis of ELEVATUM
Emmanuel Chang, Christiana Dinah, Jeremiah Brown, Jennifer Lim, Adrienne Scott, Thomas Albrecht, Manuel Amador, Michael Chang, Huanxiang Lu, Alexandra Warter, Ming Yang
Ophthalmology | Diabetic Macular Edema
Share page
Coming soon

© 2025 Genentech USA, Inc. All rights reserved. This site is intended for US HCPs only.

Learn more about MEDICALLY